Palabras clave
SARS-CoV-2
síndrome antifosfolipídico
anticuerpos antifosfolipídicos “no-criterio”
Cómo citar
Resumen
Introducción: El síndrome es una entidad caracterizada por trombosis y abortos recurrentes, asociada a títulos altos de anticuerpos antifosfolipídicos. Estos pueden surgir de manera transitoria en pacientes con enfermedad crítica e infecciones, incluyendo la COVID-19. Objetivos: Determinar los niveles de anticuerpos antifosfolipídicos y su asociación con parámetros de laboratorio en pacientes internados con diagnóstico de COVID-19. Materiales y métodos: Se realizó en el Nuevo Hospital San Roque un estudio analítico, prospectivo, correlacional y transversal de pacientes de género masculino y femenino mayores de 18 años, internados con diagnóstico de COVID-19 entre agosto de 2021 y agosto de 2022. Los niveles de anticuerpos antifosfolipídicos se determinaron con un kit comercial. Resultados: Para IgM anticardiolipinas, no se observaron diferencias estadísticamente significativas entre los pacientes control y caso, pero sí, para IgM anti-β2-glicoproteína-I e IgG anticardiolipinas y anti-β2-glicoproteína-I. En cuanto al análisis de los anticuerpos antifosfolipídicos “no-criterio”, se observaron diferencias estadísticamente significativas con respecto a IgM e IgG anticardiolipinas e IgM anti-β2-glicoproteína-I, pero no, para IgG anti-β2-glicoproteína-I. Al analizar el comportamiento a distintos intervalos de tiempo, se observaron diferencias estadísticamente significativas para IgM anticardiolipinas e IgM anti-β2-glicoproteína-I. Conclusiones: Los pacientes con COVID-19 presentan mayores niveles de anticuerpos antifosfolipídicos respecto de pacientes sin la afección.
Referencias
Núñez-Álvarez CA, Cabiedes J. Mecanismos patogénicos de los anticuerpos antifosfolípidos. Reumatol Clin. 2011; 7(1):72–76, http://dx.doi.org/10.1016/j.reuma.2009.10.005
Funke A, Staub HL, Monticielo OA, Balbi GGM, Danowski A, Santiago MB, et al. Non-criteria Antiphospholipid Antibodies: a narrative review. Revista da Associacao Medica Brasileira. 1992; 66(11):1595–1601, http://dx.doi.org/10.1590/1806-9282.66.11.1595
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Khamashta MA. International consensus statement on preliminary classification criterio for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol. 1999;42(7):1309–11, http://dx.doi.org/10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003;62(12):1127, http://dx.doi.org/10.1136/ard.2003.006163
Liu T, Gu J, Wan L et al. “Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther. 2020; 22(33), http://dx.doi.org/10.1186/s13075-020-2131-4
Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20:1802–4.
Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, Henrion D, Loufrani L, et al. Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? Autoimmunity Reviews 2020; 17(8):739–745, http://dx.doi.org/10.1016/j.autrev.2018.01.027
Pouymiró Pubillones PO, Pouymiró Brooks Y, Pouymiró Brooks I. Síndrome de anticuerpos antifosfolípidos. Medisan. 2012; 16(3):429–44.
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med. 2020; 382(17):e38, http://dx.doi.org/10.1056/NEJMc2007575
Dotan A, Muller S, Kanduc D, David P, Halpert G, et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmunity reviews. 2021; 20(4), http://dx.doi.org/10.1016/j.autrev.2021.102792
Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, et al. A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. Clin Appl Thromb Hemost. 2018; 24(3):439-445, http://dx.doi.org/10.1177/1076029617720069
Zuo Y, Estes SK, Gandhi AA, Yalavarthi S, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Science Translational Medicine. 2020; 12(570), http://dx.doi.org/10.1126/scitranslmed.abd3876
Espinoza G, Cervera R, Font J, Shoenfeld Y. Anthiphospholipid syndrome: pathogenic mechanism. Autoinmmun Rev. 2003;2:86–93, http://dx.doi.org/10.1016/s1568-9972(02)00144-1
Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, et al. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2019; 18(11):102395, http://dx.doi.org/10.1016/j.autrev.2019.102395
Tvito A, Zimmerman FS, Asher E, Helviz Y. Lupus anticoagulant in patients with COVID-19. Int J Lab Hematol. 2021; 43(1):17–18, http://dx.doi.org/10.1111/ijlh.13334
Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost. 2020; 18(8):2064–2065, http://dx.doi.org/10.1111/jth.14867
Pineton de Chambrun M, Frere C, Miyara M, Amoura Z, Martin-Toutain I, et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability? J Intern Med. 2021; 289(3):422–424, http://dx.doi.org/10.1111/joim.13126
Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020; 18(8):1995–2002, http://dx.doi.org/10.1111/jth.14888
Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020; 191:9–14, http://dx.doi.org/10.1016/j.thromres.2020.04.024
Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020; 173(4):268–277, http://dx.doi.org/10.7326/M20-2003
Amezcua-Guerra LM, Rojas-Velasco G, Brianza-Padilla M, Vázquez-Range A, Márquez-Velasco R, et al. Presence of antiphospholipid antibodies in COVID-19: case series study. Ann Rheum Dis. 2021; 80(5):e73, http://dx.doi.org/10.1136/annrheumdis-2020-218100
Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020; 18(9):2191–2201, http://dx.doi.org/10.1111/jth.14994
Siguret V, Voicu S, Neuwirth M, Delrue M, Gayat E, et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Thromb Res 2020; 195:74–6, http://dx.doi.org/10.1016/j.thromres.2020.07.016
Le Joncour A, Frere C, Martin-Toutain I, Gougis P, Ghillani-Dalbin P, et al. Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmun Rev 2021; 20(2):102729, http://dx.doi.org/10.1016/j.autrev.2020.102729
Liu X, Zhu L, Liu H, Cai Q, Yun Z, et al. Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added.
Front. Immunol. 2022; 13:972012, http://dx.doi.org/10.3389/fimmu.2022.972012
Bizzaro N, Ghirardello A, Zampieri S, Iaccarino L, Tozzoli R, et al. Antiprothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: A 15-year longitudinal study. J Thromb Haemost.
; 5(6):1158–1164, http://dx.doi.org/10.1111/j.1538-7836.2007.02532.x
Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, et al. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018; 9:2971, http://dx.doi.org/10.3389/fimmu.2018.02971
Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005;106(13):4152–4158, http://dx.doi.org/10.1182/blood-2005-05-2048
Vollmer O, Tacquard C, Dieudonne Y, Nespola B, Sattler L, et al. Followup of COVID-19 patients: LA is transient but other aPLs are persistent. Autoimmun Rev. 2021; 20(6):102822, http://dx.doi.org/10.1016/j.autrev.2021.102822
Espinosa G, Zamora-Martinez C, Perez-Isidro A, Neto D, Bravo-Gallego LY, et al. Persistent antiphospholipid antibodies are not associated with worse clinical outcomes in a prospective cohort of hospitalised patients with SARS-CoV-2 infection. Front Immunol. 2022; 13:911979,http://dx.doi.org/10.3389/fimmu.2022.911979
Xiao M, Zhang Y, Zhang S, Qin X, Xia P, et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol. 2020; 72(12):1998–2004, http://dx.doi.org/10.1002/art.41425
Sciascia S, Radin M, Bazzan M, Montaruli B, Cosseddu D, et al. Antiphospholipid antibodies and infection: non Nova Sed Nove. Front Immunol. 2021; 12:687534, http://dx.doi.org/10.3389/fimmu.2021.687534